Safety and Efficacy of Nivolumab Combined With Anlotinib in Advanced Non-small Cell Lung Cancer Patients Previously Treated With Checkpoint Inhibitor-A Single Center and Exploratory Study
Latest Information Update: 27 Jun 2024
At a glance
- Drugs Catequentinib (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Jun 2024 Results of this study presented in the BMC Cancer
- 26 Jun 2022 Status changed from recruiting to completed.
- 31 Jan 2021 Trial design presented at the 2020 World Conference on Lung Cancer.